XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
ANVS Annovis Bio
- 2.730
- +0.130+5.00%
Close Feb 14 16:00 ET
- 2.740
- +0.010+0.36%
Post 20:01 ET
53.20MMarket Cap-0.65P/E (TTM)
2.790High2.610Low506.47KVolume2.650Open2.600Pre Close1.37MTurnover3.23%Turnover RatioLossP/E (Static)19.49MShares20.00052wk High7.52P/B42.78MFloat Cap2.44052wk Low--Dividend TTM15.67MShs Float132.000Historical High--Div YieldTTM6.92%Amplitude2.418Historical Low2.703Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
Annovis Bio Stock Forum
Major Alzheimer's Breakthrough: First Patients Begin Treatment in Groundbreaking Phase 3 Trial
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease
Wednesday, 5th February at 8:00 am
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the first two...
Annovis Bio Announces That The First Two Patients Have Been Entered Into The Phase 3 Study Evaluating Buntanetap In Early AD
Benzinga· 1 min ago
Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
Tuesday, 14th January at 8:00 am
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it was granted the U.S. pa...
FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Disease Study, Streamlining Development Pathway
Tuesday, 7th January at 8:00 am
MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the FDA has accepted ...
No comment yet